ArticleMolecular diversity2026
Integrating machine learning and deep learning with multiple molecular fingerprints for topoisomerase I inhibitor screening and lead identification.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Topoisomerase I (TOP1) is a crucial anticancer target, but the development of traditional TOP1 inhibitors suffers from long research cycles, high costs, and low success rates. Existing artificial intelligence (AI)-driven studies lack systematic comparisons of molecular fingerprints and algorithms, as well as user-friendly predictive application tools. To address these gaps, this study retrieved TOP1 inhibitor activity data from the ChEMBL database, integrated five types of molecular fingerprints (AtomPairs, MACCS, Morgan, PharmacoPFP, and RDKitDes), and constructed and compared classical machine learning (ML) models and deep learning (DL) models, resulting in a total of 40 models. The four top-performing models, SVM::Morgan, RF::Morgan, DNN::MACCS, and KNN::Morgan, achieved ROC-AUC values of 0.93-0.94 under random splitting. Y-scrambling supported that the models learned non-random structure-activity relationships, while SHAP analysis identified key molecular features. The URL of the developed web application is http://drugpred.top:5000 , and this application enables the prediction of TOP1 inhibitory activity via SMILES (Simplified Molecular-Input Line-Entry System) or molecular structure drawing. Additionally, standalone desktop applications (.exe) for offline prediction are freely available at https://github.com/zenghuang8006/TOP1-inhibitor-prediction . Screening of 189,554 SPECS compounds followed by in vitro validation identified AG60 and AI61 as potential TOP1 inhibitors hits, with inhibition rates of 64% and 90% at 400 µM, respectively. Overall, this study provides a practical computational framework for TOP1 inhibitor screening and identifies promising candidate compounds. Notably, scaffold-split AUC values decreased to 0.67-0.82, indicating reduced extrapolative performance for compounds containing previously unseen scaffolds.
Indexed as
Identifiers
42693316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.